Drug intelligence / Profile preview

CYRS-1645

Development stage: Unknown
Lead developer: Yuhan
Modality: Small Molecules

Overview

CYRS-1645 (also known as KNP-504) is a small molecule drug candidate that acts as an inhibitor of Son of sevenless homolog 1 (SOS1), a key protein involved in the RAS signaling pathway. By inhibiting SOS1, the drug aims to disrupt oncogenic RAS-driven signaling implicated in various cancers. It is being developed for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. The compound has reached preclinical development stages and has not yet entered clinical trials or received regulatory approval[5].

Targets

SOS1 (Son of sevenless homolog 1)

Beyond the preview

Go deeper on CYRS-1645.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYRS-1645.

Explore the full profile